What is it about?

The use of nanomedicine (medical applications of nanotechnology) in cancer treatment has gained much interest, but certain tumors such as pancreatic cancer seem refractory. By devising a simple animal model which demonstrates increased fibrosis, a prominent characteristic of pancreatic cancer, we show that increased fibrosis results in reduced therapeutic efficacy of nanomedicine.

Featured Image

Why is it important?

Most cell-line based xenograft models of pancreatic cancer demonstrate little fibrosis, which is a prominent characteristic of this tumor. Though genetically modified murine models have been devised which recapitulate human pathology, some drawbacks are that they are time-consuming, expensive, and labor intensive. We report a simple cell-line based model that can be used to study the role of fibrosis in pancreatic cancer pathogenesis and treatment.

Read the Original

This page is a summary of: Increased fibrosis and impaired intratumoral accumulation of macromolecules in a murine model of pancreatic cancer co-administered with FGF-2, Journal of Controlled Release, May 2016, Elsevier, DOI: 10.1016/j.jconrel.2016.04.007.
You can read the full text:

Read

Resources

Contributors

The following have contributed to this page